Promega and QuantumCyte present joint poster at AMP 2024 meeting

This collaboration will focus on the joint promotion of the QuantumCyte QCPRECISE!™ precision tissue enrichment platform alongside manual and automated nucleic acid purification chemistry from Promega.

The joint marketing initiative will leverage both companies’ expertise to develop materials demonstrating the utility of combining QCPRECISE! with Maxwell^® and ReliaPrep™ extraction platforms. Service teams from both companies will also receive product training to support customers leveraging the entire workflow.

Both companies will be attending AMP 2024 Annual Meeting & Expo, Vancouver, Canada from November 19–23, to discuss workflow solutions. They will also be showcasing a poster titled: Enhanced MSI Status Determination from FFPE Tissue Sections Using an Integrated Workflow Combining QuantumCyte’s QCPRECISE!™ with Promega’s Maxwell^® CSC DNA FFPE Kit.

“The Maxwell^® CSC system complements QuantumCyte’s QCPRECISE!™ tissue enrichment technology to deliver a high-throughput and efficient solution for labs seeking to optimize their workflow efficiency,” says Alok Sharma, Global Clinical Market Director at Promega. “Additionally, the ReliaPrep™ kits cater to labs requiring adaptable solutions for lower throughput or specialized applications.”

“The QCPRECISE!™ Scan Print Extract (SPE) platform increases cellular nucleic acid purity from solid tissue biopsies for downstream multi-omic applications,” says John Butler, Chief Scientific Officer at QuantumCyte. “Through the integration with Maxwell® CSC System and ReliaPrep™ kits, a complete workflow that produces high purity nucleic acid is now available for use in commercial, research and pharma applications.”

Want the latest science news straight to your inbox? Become a SelectScience member for free today>>